Market
BlueWind Medical raises $47.8m to advance commercialisation efforts for UUI treatment
BlueWind Medical closed a $47.8 million funding round to accelerate commercialisation of its Revi implantable tibial neuromodulation system for urge urinary incontinence treatment. Proceeds will fund expanded sales operations and market access initiatives.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network